No record found


* Returns not adjusted for payouts
Company Profile
GlaxoSmithKline Pakistan Limited is incorporated in Pakistan as a limited liability company. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products. The Company is a subsidiary of S.R. One International B.V., incorporated in Netherlands, whereas its ultimate parent company is GlaxoSmithKline plc, UK (GSK plc).
Erum Shakir Rahim | CEO |
Lai Kuen Goh | Chairperson |
Hina Mir | Company Secretary |
CDC Share Registrar Services Limited CDC House, 99 - B, Block - B S.M.C.H.S., Main Shahra-e-Faisal Karachi
Yousuf Adil, Chartered Accountants
December
Equity Profile
Announcements
Date | Title | Document |
---|---|---|
Apr 29, 2025 | Transmission of Quarterly Report for the period ended March 31, 2025 | View PDF |
Apr 25, 2025 | Financial Results for the Quarter Ended March 31, 2025 | View PDF |
Apr 7, 2025 | Transmission of Annual Report for the year ended December 31, 2024 | View PDF |
Mar 24, 2025 | Financial Results for the Year Ended 31st December 2024 | View PDF |
Oct 29, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited TRANSMISSION OF QUARTERLY ACCOUNTS FOR THE PERIOD ENDED SEP. 30, 2024 | |
Oct 28, 2024 | Financial Results for the nine months ended September 30,2024 | View PDF |
Oct 28, 2024 | Financial results for the nine months ended September 20, 2024 REVOKED | View PDF |
Aug 29, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Transmission of Half yearly Report for the Period Ended June 30, 2024 | |
Aug 23, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Financial Results for the Half Year Ended June 30 2024 | |
Jul 23, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Other Than Financial Results |
Date | Title | Document |
---|---|---|
Apr 28, 2025 | Certified True Copy of the Resolutions passed by shareholders in the Annual General Meeting held on April 28, 2025 | View PDF |
Apr 17, 2025 | Board Meeting Quarter ended March 31, 2025 | View PDF |
Apr 7, 2025 | Notice of Annual General Meeting | View PDF |
Apr 4, 2025 | Prior Publication of Annual General Meeting Notice | View PDF |
Mar 14, 2025 | Board of Directors Meeting for the year ended December 31, 2024 | View PDF |
Oct 21, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Board Meeting | |
Aug 16, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Board Meeting | |
Jul 30, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited GSK Board Meeting Result other than Financial Results July 30 2024 | |
Apr 24, 2024 | Certified True Copy of Resolution passed by the Shareholders in the Annual General Meeting held on April 24, 2024 | View PDF |
Apr 19, 2024 | Board Meeting for the quarter ended March 31, 2024 | View PDF |
Date | Title | Document |
---|---|---|
May 7, 2025 | Credit of Final Cash Dividend | View PDF |
Feb 7, 2025 | Appointment of Non-Executive Director | View PDF |
Nov 18, 2024 | Material Information | View PDF |
Nov 11, 2024 | Presentation of Corporate Briefing Session 2024 | View PDF |
Nov 8, 2024 | Notice of Corporate Briefing Session - 2024 | View PDF |
Oct 4, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited UNUSUAL MOVEMENT IN THE PRICE OF SHARES OF GlaxoSmithKline Pakistan Limited | |
Jun 11, 2024 | Appointment of Company Secretary | View PDF |
Jun 10, 2024 | Resignation of Company Secretary | View PDF |
May 20, 2024 | Unusual Movement in the price of shares | View PDF |
Apr 23, 2024 | GLAXO | GlaxoSmithKline Pakistan Limited Material Information |
Financials
All numbers in thousands (000's) except EPS
2024 | 2023 | 2022 | 2021 | |
---|---|---|---|---|
Sales | 61,187,501 | 49,661,277 | 41,841,585 | 36,660,772 |
Profit after Taxation | 6,536,047 | 533,953 | 2,462,892 | 5,354,409 |
EPS | 20.52 | 1.68 | 7.73 | 16.81 |
Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | |
---|---|---|---|---|
Sales | 15,580,140 | 14,730,940 | 13,254,797 | 15,616,126 |
Profit after Taxation | 2,126,547 | 1,927,134 | 1,088,869 | 565,281 |
EPS | 6.68 | 6.05 | 3.42 | 1.78 |

Ratios
2024 | 2023 | 2022 | 2021 | |
---|---|---|---|---|
Gross Profit Margin (%) | 25.15 | 7.05 | 17.40 | 26.56 |
Net Profit Margin (%) | 10.68 | 1.08 | 5.89 | 14.61 |
EPS Growth (%) | 1,121.43 | (78.27) | (54.02) | 58.58 |
PEG | 0.02 | (0.63) | (0.21) | 0.14 |
Payouts
Date | Financial Results | Details | Book Closure |
---|---|---|---|
March 24, 2025 2:13 PM | 31/12/2024(YR) | 100%(F) (D) | 22/04/2025 - 28/04/2025 |
February 28, 2022 11:32 AM | 31/12/2021(YR) | 70%(F) (D) | 19/04/2022 - 25/04/2022 |
March 10, 2021 3:45 PM | 31/12/2020(YR) | 65%(F) (D) | 21/04/2021 - 27/04/2021 |
March 11, 2020 5:58 PM | 31/12/2019(YR) | 60%(F) (D) | 15/05/2020 - 21/05/2020 |
March 4, 2019 4:53 PM | 31/12/2018(YR) | 70%(F) (D) | 18/04/2019 - 24/04/2019 |
February 27, 2018 3:59 PM | 31/12/2017(YR) | 40% (D) | 18/04/2018 - 24/04/2018 |
October 26, 2017 5:47 PM | 30/09/2017(IIIQ) | 30% (D) | 10/11/2017 - 17/11/2017 |
March 8, 2017 4:03 PM | 31/12/2016(YR) | 60% (D) | 18/04/2017 - 24/04/2017 |
March 30, 2016 3:13 PM | 31/12/2015(YR) | 40% (D) | 20/04/2016 - 27/04/2016 |
February 25, 2015 3:51 PM | 31/12/2014(YR) | 50% (D) | 16/04/2015 - 23/04/2015 |